Did drug researchers have a lucky break when they developed antiviral drugs for influenza? Crystal structures of enzymes from the H5N1 virus suggest that they did, and provide avenues for further exploration.
This is a preview of subscription content, log in via an institution to check access.
Notes
*This article and the paper concerned1 were published online on 16 August 2006.
References
Russell, R. J. et al. doi:10.1038/nature05114 (2006).
Thompson, J. D., Higgins, D. G. & Gibson, T. J. Comput. Appl. Biosci. 10, 19–29 (1994).
Kim, C. U. et al. J. Am. Chem. Soc. 119, 681–690 (1997).
von Itzstein, M. et al. Nature 363, 418–423 (1993).
Taylor, N. R. et al. J. Med. Chem. 41, 798–807 (1998).
Warren, M. K. et al. Antimicrob. Agents Chemother. 46, 1014–1021 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luo, M. Antiviral drugs fit for a purpose. Nature 443, 37–38 (2006). https://doi.org/10.1038/nature05003
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature05003
- Springer Nature Limited
This article is cited by
-
Revealing lost secrets about Yingpan Man and the Silk Road
Scientific Reports (2022)
-
Paleoclimatic information recorded in fluid inclusions in halites from Lop Nur, Western China
Scientific Reports (2017)
-
Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains
Scientific Reports (2017)
-
Global transcriptomic analysis of an engineered Escherichia coli strain lacking the phosphoenolpyruvate: carbohydrate phosphotransferase system during shikimic acid production in rich culture medium
Microbial Cell Factories (2014)
-
The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site
Nature Structural & Molecular Biology (2010)